Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery

American Journal of Ophthalmology

Volumn 151, Issue 3, 2011, Pages

  Donnenfeld, Eric D ^a   Nichamin, Louis D ^b   Hardten, David R ^c   Raizman, Michael B ^d   Trattler, William ^e   Rajpal, Rajesh K ^f   Alpern, Louis M ^g   Felix, Carlos ^h   Bradford, Ronald R ^h   Villanueva, Linda ^h   Hollander, David A ^h   Schiffman, Rhett M ^h  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^b Laurel Eye Clinic   (United States)

^c MINNESOTA EYE CONSULTANTS   (United States)

^d OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^e Center for Excellence in Eye Care Florida   (United States)

^f Cornea Consultants ^*  (United States)

^g Cataract and Glaucoma Center   (United States)

^h ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUVAIL; KETOROLAC; UNCLASSIFIED DRUG;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; BLURRED VISION; CATARACT; CATARACT EXTRACTION; CHEMOSIS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EYE BURNING; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYELID EDEMA; FACE PAIN; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRITIS; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PHOTOPHOBIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 79951810268     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.09.003     Document Type: Article

References (32)

1. El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2001;12(1):4-8. (Pubitemid 32113605)
2. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18(7): 790-804. (Pubitemid 38544498)
3. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000;11(1):3-6. (Pubitemid 30060889)
4. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21(7):1131-1137. Erratum in Curr Med Res Opin 2005;21(9):1431-1432.
5. Raizman MB, Donnenfeld ED, Weinstein AJ. Clinical comparison of two topical prednisolone acetate 1% formulations in reducing inflammation after cataract surgery. Curr Med Res Opin 2007;23(10):2325-2331. (Pubitemid 350033434)
6. Rossetti L, Autelitano A. Cystoid macular edema following cataract surgery. Curr Opin Ophthalmol 2000;11(1):65-72. (Pubitemid 30060897)
7. Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1990;39(1):86-109.
8. Acular LS [package insert]. Irvine, CA: Allergan, Inc.; 2008.
9. Acular [package insert]. Irvine, CA: Allergan, Inc.; 1997.
10. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127(3):253-259. (Pubitemid 29128121)
11. Solomon KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108(2):331-337. (Pubitemid 32115965)
12. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30(8):1653-1660. (Pubitemid 39094372)
13. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006;22(6):1133-1140. (Pubitemid 44000733)
14. Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146(4):554-560.
15. Acuvail [package insert]. Irvine, CA: Allergan, Inc.; 2009.
16. Sasaki H, Yamamura K, Mukai T, et al. Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle. Biol Pharm Bull 2000;23(11): 1352-1356.
17. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004; 20(12):2015-2019. (Pubitemid 40179640)
18. Dinning WJ. Steroids and the eye - indications and complications. Postgrad Med J 1976;52(612):634-638.
19. Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg 2006;32(9):1474-1482. (Pubitemid 44247473)
20. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7(1):99-107.
21. Lundberg B, Behndig A. Separate and additive mydriatic effects of lidocaine hydrochloride, phenylephrine, and cyclopentolate after intracameral injection. J Cataract Refract Surg 2008;34(2):280-283. (Pubitemid 351173620)
22. Nikeghbali A, Falavarjani KG, Kheirkhah A. Pupil dilation with intracameral lidocaine during phacoemulsification: Benefits for the patient and surgeon. Indian J Ophthalmol 2008;56(1):63-64.
23. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150(9):1881-1884. (Pubitemid 20316533)
24. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behaviour - a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991;41(6):589-592.
25. Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2007;48(4):1559-1567. (Pubitemid 351261339)
26. Kim SJ, Lo WR, Hubbard GB III, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Arch Ophthalmol 2008; 126(9):1203-1208.
27. Henry JC, Olander K. Comparison of the effect of four viscoelastic agents on early postoperative intraocular pressure. J Cataract Refract Surg 1996;22(7):960-966.
28. Rich WJ, Radtke ND, Cohan BE. Early ocular hypertension after cataract extraction. Br J Ophthalmol 1974;58(8):725-731.
29. Vasavada AR, Mamidipudi PR, Minj M. Relationship of immediate intraocular pressure rise to phaco-tip ergonomics and energy dissipation. J Cataract Refract Surg 2004;30(1): 137-143. (Pubitemid 38234344)
30. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987;28(3): 477-481. (Pubitemid 17040855)
31. Tran VT, Mermoud A, Herbort CP. Appraisal and management of ocular hypotony and glaucoma associated with uveitis. Int Ophthalmol Clin 2000;40(2):175-203. (Pubitemid 30235949)
32. Nevanac [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2005.